Failed study sends XOMA shares reeling after the bell Print E-mail
By BioMedReports.com Staff   
Tuesday, 22 March 2011 19:21
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 22, 2011.


After the bell, shares of XOMA Ltd. (Nasdaq:XOMA), plunged after the company announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint, lowering of blood sugar in patients, after six monthly treatments with XOMA 052 compared to placebo. The company reported that the drug did however cut levels of c-reactive protein, a substance which is associated with the risk of a heart attack or stroke. The study indicated that the drug might be useful for other indications, in particular heart disease and Behcet's uveitis, an ifflamation of the eye. The company said it plans to expand clinical trials for those indications sometime this year.

After the bell, shares dropped $1.92 or 38% to $3.10.

Spectrum Pharmaceuticals (NasdaqGS:SPPI), announced today that the FDA has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the “bioscan” requirement. A decision is expected by November 20, 2011.

Axia Group (PINK SHEETS:AGIJ) subsidiary Collagenna Skin Care Products/Melem Secret is pleased to announce that it has received several promising inquiries from companies in China that are interested in distributing its anti-aging products.

CNS Response, Inc. (OTCBB:CNSO) today announced that retired U.S. Marine Colonel Stewart Navarre has been named the company's vice president, customer relations, and will head its military sector efforts for the company's Referenced-EEG®.Referenced-EEG (rEEG®) is an online database providing medical professionals with information on mental health medication response in patients.

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX) manufacturer and distributor of the MedFlash®, the nation's premier Personal Health and Wellness Management System (ePHM) for maintaining personal health records (PHR), announced today that MedFlash® will be a preferred vendor of the National EYEPA'stwenty-seven state IPAs representing approximately 4,500 doctors -- 4,200 OD's (Doctors of Optometry) and 300 MD's and a total of 6,600 "Doctor Locations."

Fresh Start Private (OTCBB: CEYY)
, a leader in the alcohol treatment and rehabilitation industry, announced today that it is processing over $1 Million dollars in insurance claims at its Orange Country clinic for the month of February 2011.

Given Imaging (NASDAQ: GIVN) today announced that Yuval Yanai, Chief Financial Officer, will present at the 10th Annual Needham Healthcare Conference taking place April 5 - 6, 2011 in New York City.

MedLink (OTCQB: MLKNA), a leading provider of clinical software and healthcare IT solutions, announced today that it has entered into a agreement with Baptist Health South Florida, the largest faith based, not-for-profit health care organization in Florida as one of the vendors to participate in Baptist Health's EHR (Electronic Health Record) Donation Program.

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS:TRDX) is pleased to announce that Preferred Distribution, Inc., its medical/dental supply distribution subsidiary, has received payment from its recently generated purchase orders from its new pharmaceutical distribution division.

Sionix Corporation (OTCBB: SINX), designer of innovative and patented, advanced mobile water treatment systems, is pleased to announce that it has entered into an agreement with SAJ Consult LLC (SAJC) of Las Vegas, NV to represent certain Sionix interests in the People's Republic of China (PRC) and other countries in South and Southeast Asia.

Visual Healthcare Corp. (PINKSHEETS: VSHC) announces that it is breaking new grounds in providing the pharmaceutical industry with highly flexible and secure tools for gathering clinical data from multiple sources around the globe for research purposes.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter